Hypertension,Essential: Clinical Trials

5 trials for Hypertension,Essential, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 unknown, 1 not yet recruiting. 5 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 35Completed 2, Unknown 2, Not yet recruiting 1

Follow Hypertension,Essential: new trials by email Literature Review of Hypertension,Essential trials Research Report on Hypertension,Essential

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
Dehydrated Alcohol Injection, USP, Sham procedure - Hypertension, Hypertension,Essential
Phase 3Not yet recruitingAblative Solutions, Inc.2022026-10-012026-08-20
Phase III Study to Evaluate the Efficacy and Safety of AD-209
AD-209, AD-2091, AD-209 Placebo - Hypertension,Essential
Phase 3UnknownAddpharma Inc.2802024-05-202024-05-21
A Study to Evaluate the Efficacy and Safety of AD-224
AD-224A, AD-224B, AD-224C - Hypertension,Essential
Phase 3CompletedAddpharma Inc.2542024-04-152026-08-03
A Study to Evaluate the Efficacy and Safety of AD-223
AD-223A, AD-223B, AD-223C - Hypertension,Essential
Phase 3CompletedAddpharma Inc.5022024-02-152025-04-04
Efficacy and Safety Study of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension.
fixed-dose of olmesartan 20mg/40 mg + indapamide 1,5 mg, Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg) - Hypertension, Hypertension,Essential
Phase 3UnknownBrainfarma Industria Química e Farmacêutica S/A4002022-08-012022-03-21

Narrower conditions

Essential Hypertension (5)  ·  Hypertension (2)

Broader conditions

Cardiovascular Diseases (5)  ·  Vascular Diseases (5)  ·  Hypertension (3)

Interventions

Ethanol (1)  ·  Indapamide (1)  ·  olmesartan (1)

Sponsors

Addpharma Inc. (3)  ·  Ablative Solutions, Inc. (1)  ·  Brainfarma Industria Química e Farmacêutica S/A (1)

Countries

South Korea (3)  ·  United States (1)

Top investigators

Atul Pathak, Prof. (1)  ·  Chang Gyu Park, M.D., Ph.D (1)  ·  David Kandzari, MD (1)  ·  Felix Mahfoud, Prof.Dr. med (1)  ·  Gregg Stone, MD (1)  ·  InHo Chae, M.D., Ph.D (1)  ·  Jin Ho Shin, M.D., Ph.D (1)  ·  Michael Weber, MD (1)

Results publications

PMID 41717679, PMID 42130156